Resource Library Search

Resource Library Search Filter

Filter By Resource Library: Format Type

Website (34)

Journal Article (20)

Booklet (13)

Guidelines (13)

Fact Sheet (10)

Video (6)

Palm Card (6)

Consensus Recommendations (4)

Worksheet (3)

Referral Form (3)

Webinar (2)

Filter By Resource Library: Topic

Assess (113)

Implement the Initiative (107)

Learn (107)

Prepare the Care Team (101)

Patient Education (64)

B-cell ALL (54)

Lay the Groundwork (50)

Multiple Myeloma (50)

CLL (42)

MRD Testing Methods (24)

Treatment Decision-Making (21)

Financial Resources (16)

Timing of MRD Testing (8)

Clinical Trials (8)

Treatment (7)

Social & Emotional Support (6)

Act (6)

Evaluate Your Progress (6)

Evaluation (6)

MRD Testing Facilities (6)

Resource Library Search

You searched for:

Assess

Displaying results 21 - 40 of 113

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

This review article presents "the work of an international, multidisciplinary, 174-member panel convened to identify critical questions on key issues pertaining to MRD in chronic lymphocytic leukemia, review evaluable data, develop unified answers in conjunction with local expert input, and provide recommendations for future studies. Recommendations are presented regarding methodology for MRD determination, assay requirements and in which tissue to assess MRD, timing and frequency of assessment, use of MRD in clinical practice versus clinical trials, and the future usefulness of MRD assessment.

Leukemia

Assess Clinical Trials CLL Implement the Initiative Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

Detection of MRD in CLL is becoming increasingly important as treatments improve...There was good correlation between four-CLR and six-CLR panels in dilution studies and clinical samples, with 100% concordance for detection of residual disease at the 0.01% (10?4) level (n=59) and good linearity even at the 0.001�0.01% (10?5�10?4) level. A six-CLR panel therefore provides equivalent results to the four-CLR panel but it requires fewer reagents, fewer cells and a much simpler analysis approach.

Leukemia

Assess CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Journal Article

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

In CLL the level of MRD after therapy is an independent predictor of outcome�A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.

Leukemia

Assess CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Journal Article

Measurable residual disease in multiple myeloma: ready for clinical practice?

The landscape of multiple myeloma has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess MRD as the most accurate method to evaluate treatment efficacy. The sensitivity and standardization achieved by these techniques together with unprecedented rates of CR induced by new regimens, raised enormous interest in MRD as a surrogate biomarker of patients� outcome and endpoint in clinical trials. By contrast, there is reluctance and general lack of consensus on how to use MRD outside clinical trials. Here, we discuss critical aspects related with the implementation of MRD in clinical practice.

Journal of Hematology & Oncology

Assess Clinical Trials Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Minimal residual disease in multiple myeloma: why, when, where

We review the data supporting MRD testing as well as its limitations and how it may fit in with current and future clinical practice.

Hematology

Assess Implement the Initiative Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Journal Article

Minimal residual disease assessment in multiple myeloma patients: minimal disease with maximal implications

This review examines the different methods used to detect MRD and discusses future considerations regarding the implementation in day-to-day clinical practice and as a prospective primary endpoint for clinical trials.

Frontiers in Oncology

Assess Clinical Trials Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Journal Article

The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia

"This monograph examines clinical trial data regarding the role of MRD in CLL, and provides recommendations on how to incorporate MRD assessment into clinical management."

Clinical Advances in Hematology & Oncology

Assess Clinical Trials CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma

Based on available evidence correlating attainment of MRD negativity with outcomes, MRD assessment has been incorporated into ongoing clinical trials. Analyses will provide additional insight into the correlation between MRD and outcome. This monograph examines the available trial data and provides recommendations on how to incorporate MRD assessment into clinical management.

Clinical Advances in Hematology & Oncology

Assess Implement the Initiative Learn MRD Testing Methods Prepare the Care Team Journal Article

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia

This article shows that poor early MRD response, in contrast to conventional ALL risk factors, is an excellent tool to identify patients who may benefit from allogeneic SCT in the context of intensified adult ALL therapy.

Blood

Assess B-cell ALL Implement the Initiative Learn Prepare the Care Team Treatment Decision-Making Journal Article

NCCN Guidelines for Multiple Myeloma

NCCN offers clinical guidelines to guide the treatment and care of patients with multiple myeloma. (Create a free account profile to access guidelines.)

National Comprehensive Cancer Network (NCCN)

Assess Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Treatment Treatment Decision-Making Guidelines

NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCCN offers clinical guidelines to guide the treatment and care of patients with CLL. (Create a free account profile to access guidelines.)

National Comprehensive Cancer Network (NCCN)

Assess CLL Implement the Initiative Lay the Groundwork Learn Prepare the Care Team Treatment Treatment Decision-Making Guidelines

NCCN Guidelines for Acute Lymphoblastic Leukemia

NCCN offers clinical guidelines to guide the treatment and care of patients with ALL. (Create a free account profile to access guidelines.)

National Comprehensive Cancer Network (NCCN)

Assess B-cell ALL Implement the Initiative Lay the Groundwork Learn Prepare the Care Team Treatment Treatment Decision-Making Guidelines

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline

The ASCO Expert Panel determined that the recommendations from the guideline, published in 2016, are clear, thorough, and based on the most relevant scientific evidence. ASCO fully endorsed the CAP-ASH guideline on initial diagnostic work-up of acute leukemia and included some discussion points according to clinical practice and updated literature.

Journal of Clinical Oncology

Assess B-cell ALL Implement the Initiative Learn Prepare the Care Team Treatment Decision-Making Guidelines

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology

The guideline provides a framework for the multiple steps, including laboratory testing, in the evaluation of acute leukemia samples. Some aspects of the guideline, especially molecular genetic testing in acute leukemia, are rapidly changing with new supportive literature, which will require on-going updates for the guideline to remain relevant.

Archives of Pathology & Laboratory Medicine

Assess B-cell ALL Implement the Initiative Learn Prepare the Care Team Treatment Decision-Making Guidelines

Minimal/Measurable Residual Disease (MRD) Chart

This handout provides an overview of MRD for individuals with blood cancer.

The Leukemia and Lymphoma Society (LLS)

Assess B-cell ALL CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Patient Education Prepare the Care Team Fact Sheet

Cancer Molecular Profiling

This handout provides an overview of cancer molecular profiling and its implications in the treatment of blood cancer.

The Leukemia and Lymphoma Society (LLS)

Assess B-cell ALL CLL Implement the Initiative Learn Multiple Myeloma Patient Education Prepare the Care Team Fact Sheet

Facilities Conducting MRD Testing

The following is a list of facilities that are CLIA-certified and accept external MRD samples. Amgen neither recommends nor endorses, and may or may not have financial relationships with, any facility that appears on this list. This list is not intended to be a comprehensive list nor as a referral to any provider listed. If you would like to suggest a facility to be added to this list, please contact Amgen MedInfo at 800-77-AMGEN.

Amgen

Assess B-cell ALL CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Facilities Multiple Myeloma Fact Sheet

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

The International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments.

The Lancet Oncology

Assess Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Consensus Recommendations Journal Article

International Myeloma Working Group (IMWG) Publications

"From doctors to patients, the goal of these publications is to help anyone better understand aspects of myeloma. The information provided in the International Myeloma Working Group�s publications seeks to help guide patients and their doctors to treating myeloma in the most effective way for every individual case."

International Myeloma Foundation (IMF)

Assess Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Consensus Recommendations

The ALL Guide: Information for Patients and Caregivers

This booklet provides information for patients and their families about ALL.

The Leukemia and Lymphoma Society (LLS)

Assess B-cell ALL Implement the Initiative Learn Patient Education Prepare the Care Team Booklet

Displaying results 21 - 40 of 113

Share

In This Section

Resource Library Search Filter

Resource Library Search

Share

In This Section

Resource Library Search Filter

Resource Library Search

Sharing Article: